Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating (NASDAQ:RPRX)Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating (NASDAQ:RPRX)
Solskin On 08/08/2024, Royalty Pharma plc (NASDAQ:RPRX) presented its Q2 earnings. Following a solid Q1, the company raised its 2024[...]